Ruth Neale shares her thoughts on day two of the inaugural Solutions for Drug-Resistant Infections (SDRI) conference in Brisbane, Australia, highlighting key talks and research updates.
Disarming pathogens: benefits and challenges of antimicrobials that target bacterial virulence instead of growth and viability
This editorial presents some of the latest evidence to support the antivirulence approach, highlighting at the same time some of the issues that need to be considered when evaluating antivirulence drugs.
Ruth Neale, Outreach Program Coordinator for the Community for Open Antimicrobial Drug Discovery, (CO-ADD) reports on the inaugural Solutions for Drug-Resistant Infections (SDRI) conference in Brisbane, Australia.
Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery (CO-ADD) discusses his work towards uncovering compounds with antibiotic potential and shares his thoughts on the best strategies to tackle antibiotic resistance moving forwards.
The WHO has published a report this week listing 12 families of antibiotic-resistant bacteria that are thought to pose the greatest public health risk and should be the focus for new treatments.
Could nanoconstructs be utilized to fight infection? This Editorial discusses the potential of photoactivatable nanodrugs to overcome the growing problem of acquired antibiotic resistance in bacteria as well as the intrinsic resistance of biofilm-associated infections.
Rapid diagnostic tests for detecting emerging antibiotic resistance are mostly available and should be used now state authors Patrice Nordmann and Laurent Poirel (University of Fribourg, Switzerland). This exclusive opinion piece discusses available diagnostics and why we should take action.
New study suggests that vancomycin should be the antibiotic of choice for Clostridium difficile infections
A study including over 10,000 patients has demonstrated a lower risk of all-cause 30-day mortality when Clostridium difficile infections are treated with vancomycin as opposed to metronidazole.
Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections
This perspective discusses the urgent need for novel and efficient antimicrobial strategies against C. difficile and the authors evaluate the application of the acyldepsipeptides family of antibiotics to treat C. difficile infections.